Business Context and Reporting Period
Immunome, Inc. (IMNM) filed this Form 8-K to report the results of its 2026 Annual Meeting of Stockholders held on June 9, 2026. As of the record date of April 16, 2026, there were 113,249,519 shares of common stock outstanding and entitled to vote.
Key Financial Metrics
This filing is a current report regarding corporate governance and does not contain financial performance data. The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Voting Results
The filing details the final voting outcomes for four proposals:
- Proposal 1 (Election of Directors): Stockholders elected three Class III directors to serve until the 2029 Annual Meeting.
- James Boylan: 70,209,570 votes For; 22,171,996 votes Withheld.
- Sandra Swain, M.D.: 92,157,301 votes For; 224,265 votes Withheld.
- Philip Wagenheim: 92,162,632 votes For; 218,934 votes Withheld.
- Proposal 2 (Ratification of Auditors): Stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- Result: 104,100,900 votes For; 27,134 votes Against; 22,110 Abstentions.
- Proposal 3 (Say-on-Pay): Stockholders approved, on an advisory basis, the compensation of named executive officers.
- Result: 90,908,436 votes For; 1,442,116 votes Against; 31,014 Abstentions.
- Proposal 4 (Frequency of Say-on-Pay): Stockholders indicated a preference for the frequency of future advisory votes on executive compensation.
- Result: 91,949,591 votes for 1 Year; 368,407 votes for 2 Years; 41,534 votes for 3 Years.
Guidance, Outlook, and Management Commentary
Based on the voting results for Proposal 4, the Company determined that future stockholder advisory votes on named executive officer compensation will be held every year until the next required advisory vote on frequency. The filing contains no financial guidance, risk factors, or management commentary regarding business operations.
Important Facts for Investors to Verify
- Verify the significant number of votes withheld for director James Boylan (22,171,996) compared to the other two nominees.
- Confirm the total number of broker non-votes (11,768,578) which impacted the voting power on director elections and executive compensation proposals.
- Review the definitive proxy statement filed on April 24, 2026, for detailed biographies of the elected directors and the specific compensation packages approved.